Posted on 1/9/19
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Healthcare's biggest event of the year is now under way -- the J.P. Morgan Healthcare Conference. Over the past several years, Celgene (NASDAQ:CELG) has traditionally kicked . . .
Posted on 1/9/19
Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019, the . . .
Posted on 1/8/19
CENTOGENE Provides Corporate and Business Unit Update
ROSTOCK, Germany--(BUSINESS WIRE)--CENTOGENE is pleased to provide a corporate update, including recent business unit developments and a look ahead to 2019.“This past year saw CENTOGENE realizing . . .
Posted on 1/8/19
Tekscan's Gait Analysis System Wins R&D 100 Award
Tekscan is thrilled to announce that StridewayTM has won an R&D 100 Award.The R&D 100 Awards honor the latest and best innovations, identifying the top technology . . .
Posted on 1/8/19
FierceHealthcare recognizes Medisafe as a 2019 "Fierce 15" Healthcare Company
Medisafe, the leading global digital medication management platform, today announced that FierceHealthcare has named the company to its "Fierce 15" for 2019, designating Medisafe as one . . .
Posted on 1/8/19
T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical . . .
Posted on 1/8/19
Boston Scientific 2018 Sales Close To $10B
On a preliminary basis, Boston Scientific (NYSE:BSX) generated $9.82B in sales in 2018, up ~$8.6%. Q4 sales were $2.56B, up ~6.3%.Q4 sales growth by business ranged . . .
Posted on 1/8/19
Bristol-Myers/Celgene: Win-Win Merger
SummaryBristol-Myers agreed to pay a 54% premium to acquire Celgene.Celgene shareholders get an immediate price boost plus the long-term potential to participate in cheap BMY stock.The . . .
Posted on 1/8/19
Should Investors Like Bristol-Myers' Buyout of Celgene?
The first big merger of the year has arrived, in the form of a deal for Bristol-Myers Squibb (NYSE:BMY) to swallow Celgene (NASDAQ:CELG). The two are . . .
Posted on 1/8/19
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Healthcare's biggest event of the year is now under way -- the J.P. Morgan Healthcare Conference. Over the past several years, Celgene (NASDAQ:CELG) has traditionally kicked . . .
Posted on 1/8/19
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, . . .
Posted on 1/8/19
Organogenesis Holdings Receives Positive Nasdaq Listing Determination
Organogenesis Holdings Inc. (Nasdaq: ORGO; ORGOW) today announced that on January 4, 2019, the Company was notified by The Nasdaq Stock Market LLC that, based on the . . .
Posted on 1/7/19
Bioasis Announces Agreement With Leading Pharmaceutical Company
GUILFORD, Conn.--(BUSINESS WIRE)--Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the . . .
Posted on 1/7/19
Purdue Pharma L.P. and Ocular Therapeutix Announce Initiation of Collaborative Research Activities
STAMFORD, Conn. & BEDFORD, Mass.--(BUSINESS WIRE)--Purdue Pharma L.P. and Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies, . . .
Posted on 1/7/19
4G Clinical Achieves Advanced Technology Partnership Status with Amazon Web Services
4G Clinical, a cutting-edge randomization and trials supply management (RTSM) provider, today announced that it has achieved Advanced Technology Partner status in the Amazon Web Services . . .
Posted on 1/7/19
Infinity Pharmaceuticals Provides 2019 Goals and Financial Guidance
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced anticipated 2019 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) . . .
Posted on 1/7/19
Decibel Therapeutics and Cocoon Biotech Announce Collaboration
Decibel Therapeutics and Cocoon Biotech today announced a research collaboration to apply Cocoon's proprietary silk fibroin platform to the development of therapeutics for hearing and balance . . .
Posted on 1/7/19
Sigilon Therapeutics and MIT Announce Research Collaboration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. . . .
Posted on 1/7/19
Apic Bio Announces $40M Series A Financing
Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases
Posted on 1/7/19
Mercy Hospital St. Louis Purchases Mevion Compact Proton Therapy System
LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems has announced it has signed a contract with Mercy Hospital St. Louis for the purchase of a MEVION S250i Proton Therapy . . .
Posted on 1/7/19
Frequency Therapeutics Completes $42 Million Series B Financing
Frequency Therapeutics, a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells
Posted on 1/7/19
Factory CRO and Boston Biomedical Associates Merge
Factory-CRO Group, a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and Boston Biomedical Associates(
Posted on 1/7/19
Advent International To Acquire Majority Stake In Aimbridge Hospitality
Advent International, one of the largest and most experienced global private equity investors, today announced that it has signed a definitive agreement to acquire a majority . . .
Posted on 1/7/19
Keros Therapeutics Receives $23 Million Series B Funding
Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, announced a $23 million Series B financing today.
Posted on 1/7/19
Stealth BioTherapeutics Files For $86 Million U.S. IPO
SummaryStealth BioTherapeutics aims to sell $86.25 of its common stock in an IPO.The firm is advancing drug candidates for the treatment of mitochondrial-based conditions.MITO is in . . .

